Deciphera Pharmaceuticals Presents Results from ctDNA Analysis of INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series SessionBusiness Wire • 01/24/23
Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common StockBusiness Wire • 01/20/23
Deciphera Pharmaceuticals Announces Planned 2023 Corporate Milestones to Support Continued Evolution to Multi-Product CompanyBusiness Wire • 01/03/23
Deciphera Pharmaceuticals Announces Results from ctDNA Analysis from INTRIGUE Phase 3 Clinical Study Demonstrating Substantial Clinical Benefit of QINLOCK® in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18 OnlyBusiness Wire • 01/03/23
Deciphera Pharmaceuticals, Inc. to Present at the 41st Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/03/23
Deciphera Pharmaceuticals, Inc. to Present at the JMP Securities Hematology and Oncology SummitBusiness Wire • 12/01/22
Deciphera Pharmaceuticals, Inc. to Participate in Upcoming Investor ConferencesBusiness Wire • 11/08/22
Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2022 Financial ResultsBusiness Wire • 11/03/22
Deciphera Pharmaceuticals, Inc. to Announce Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 3, 2022Business Wire • 10/27/22
Is Deciphera Pharmaceuticals (DCPH) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 10/04/22
Deciphera Pharmaceuticals, Inc. Presents Updated Phase 1/2 Data for Vimseltinib in TGCT at the European Society for Medical Oncology (ESMO) Congress 2022Business Wire • 09/11/22
Deciphera Pharmaceuticals, Inc. Presents Initial Phase 1 Single Agent Dose Escalation Data for First-in-Class ULK Inhibitor of Autophagy, DCC-3116, at the European Society for Medical Oncology (ESMO) Congress 2022Business Wire • 09/10/22
Deciphera Pharmaceuticals, Inc. to Host Virtual Investor Event Featuring Key Opinion Leaders to Discuss DCC-3116 and Vimseltinib Data Presented at ESMO Congress 2022Business Wire • 09/01/22
Deciphera Pharmaceuticals, Inc. Announces Publication of INTRIGUE Phase 3 Clinical Study Results in Journal of Clinical OncologyBusiness Wire • 08/10/22
Deciphera Pharmaceuticals, Inc. (DCPH) CEO Steven Hoerter on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/07/22
Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2022 Financial ResultsBusiness Wire • 08/04/22
Deciphera Pharmaceuticals, Inc. to Announce Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 4, 2022Business Wire • 07/28/22